(Q45471787)

English

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

author name string

Oliver J Rackham

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kentigern Thorburn

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Steve J Kerr

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Cardiology in the Young

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

251-255

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic analysis of palivizumab in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of morbidity in interhospital transport by specialized pediatric staff.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of respiratory syncytial virus infection in infants

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Reported adverse drug events in infants and children under 2 years of age.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000533

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1047951105000533

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45471787&oldid=2076973062"